ImmunoGen, Inc. Announces Canaccord Genuity Growth Conference Webcast

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the Company will participate in the Canaccord Genuity 35th Annual Growth Conference. ImmunoGen President and CEO Daniel Junius will discuss the Company in a “fireside chat” moderated question and answer session that will be webcast beginning at 1 pm ET on August 12, 2015.

This webcast will be accessible live through the "Investors" section of the Company's website, www.immunogen.com; a replay will be available at the same location for approximately a week.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The Company utilizes its ADC technology with its antibodies to create ImmunoGen product candidates and also out-licenses limited rights to use its technology to other companies. Roche’s Kadcyla® is the first marketed product with ImmunoGen’s ADC technology. More information about the Company can be found at www.immunogen.com.

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150810006018/en/

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
[email protected]
or
For Media:
Pure Communications, Inc.
Dan Budwick, 973-271-6085

Source: ImmunoGen, Inc.

You May Also Be Interested In

• Rani Therapeutics names former Arcellx CFO to its board
• Creatio's Quarterly Bookings Reach 255% of Prior-Year Results as Enterprises Adopt AI at Scale
• Florida Cancer Specialists & Research Institute Expands Martin County Team with Elizabeth Blowers, MD, PhD